| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
25,940,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Immuneering is focused on improving patient outcomes by improving a pipeline of oncology and neuroscience product candidates developed using Co.'s translational bioinformatics platform. Co.'s development programs in oncology is focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and mTOR pathways. Co.'s primary product candidate, IMM-1-104, is designed to be a selective dual-mitogen-activated protein kinase kinase inhibitor that further disrupts kinase suppressor of RAS 1 and 2 to modulate the signaling dynamics of the MAPK pathway. In addition to IMM-1-104, Co. has six other oncology programs in the discovery stage.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
197,083 |
197,083 |
197,083 |
208,634 |
| Total Buy Value |
$477,955 |
$477,955 |
$477,955 |
$532,255 |
| Total People Bought |
8 |
8 |
8 |
11 |
| Total Buy Transactions |
11 |
11 |
11 |
15 |
| Total Shares Sold |
1,309,091 |
1,309,091 |
1,309,091 |
1,309,091 |
| Total Sell Value |
$3,909,184 |
$3,909,184 |
$3,909,184 |
$3,909,184 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
3 |
3 |
3 |
3 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Feinberg Peter |
|
– • – |
2021-09-13 |
4 |
B |
$21.25 |
$7,416 |
D/D |
349 |
349 |
0.01 |
- |
|
| Feinberg Peter |
|
– • – |
2021-09-13 |
4 |
B |
$21.51 |
$123,697 |
I/I |
5,750 |
392,242 |
0.01 |
- |
|
| Zeskind Benjamin J. |
PRESIDENT AND CEO |
• • • |
2021-09-13 |
4 |
B |
$22.87 |
$47,632 |
D/D |
2,083 |
2,602,352 |
0.01 |
- |
|
| Cormorant Private Healthcare Fund Iii Lp |
10% Owner |
– – • |
2021-08-03 |
4 |
B |
$15.00 |
$8,250,000 |
I/I |
550,000 |
2,252,628 |
1.5 |
- |
|
| Cormorant Private Healthcare Fund Iii Lp |
10% Owner |
– – • |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,702,628 |
1,702,628 |
|
- |
|
| Hall Brett Matthew |
Chief Scientific Officer |
• – – |
2021-08-03 |
4 |
B |
$15.00 |
$20,295 |
D/D |
1,353 |
6,393 |
2.74 |
- |
|
| Hall Brett Matthew |
Chief Scientific Officer |
• – – |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,040 |
5,040 |
|
- |
|
| Amin Biren |
CFO, Treasurer |
• – – |
2021-08-03 |
4 |
B |
$15.00 |
$62,625 |
D/D |
4,175 |
6,898 |
2.74 |
- |
|
| Amin Biren |
CFO, Treasurer |
• – – |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,723 |
2,723 |
|
- |
|
| Carpenter Robert J |
Director |
– • – |
2021-08-03 |
4 |
B |
$15.00 |
$4,875,000 |
D/D |
325,000 |
1,148,839 |
2.39 |
- |
|
| Carpenter Robert J |
Director |
– • – |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
217,173 |
823,839 |
|
- |
|
| Zeskind Benjamin J. |
President and CEO |
• • • |
2021-08-03 |
4 |
B |
$15.00 |
$31,470 |
D/D |
2,098 |
2,600,269 |
3.23 |
- |
|
| Zeskind Benjamin J. |
President and CEO |
• • • |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
49,099 |
2,598,171 |
|
- |
|
| Keating Laurie |
Director |
– • – |
2021-08-03 |
4 |
B |
$15.00 |
$105,000 |
D/D |
7,000 |
7,000 |
2.39 |
- |
|
| Barrett Scott |
Chief Medical Officer |
• – – |
2021-08-03 |
4 |
B |
$15.00 |
$10,005 |
D/D |
667 |
6,663 |
2.74 |
- |
|
| Barrett Scott |
Chief Medical Officer |
• – – |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,996 |
5,996 |
|
- |
|
| Berman Ann E |
Director |
– • – |
2021-08-03 |
4 |
B |
$15.00 |
$52,500 |
D/D |
3,500 |
3,500 |
2.39 |
- |
|
| Feinberg Peter |
Director |
– • – |
2021-08-03 |
4 |
B |
$15.00 |
$4,375,005 |
I/I |
291,667 |
115,441 |
2.1 |
- |
|
| Feinberg Peter |
Director |
– • – |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
338,835 |
82,108 |
|
- |
|
| Bookman Michael |
General Counsel and Secretary |
• – – |
2021-08-03 |
4 |
B |
$15.00 |
$21,030 |
D/D |
1,402 |
1,402 |
2.74 |
- |
|
| Feinberg Peter |
Director |
– • – |
2021-07-29 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
348,046 |
|
- |
|
21 Records found
|
1
|
Page 1 of 1 |
|
|
